10 May 2021 Posted By : Nolan Barton

More people develop blood clots after receiving the Janssen COVID-19 vaccin

(Natural News) The European Medicines Agency (EMA) on Friday, April 9, said that one person died after having received Johnson & Johnson’s Wuhan coronavirus (COVID-19) vaccine, also known as the Janssen vaccine. The person was one of four patients who had developed unusual blood clots after receiving the vaccine.

“Four serious cases of unusual blood clots with low blood platelets have been reported post-vaccination with COVID-19 vaccine Janssen. One case occurred in a clinical trial and three cases occurred during the vaccine rollout in the United States. One of them was fatal,” the agency said in a statement.

Janssen is a subsidiary of Johnson & Johnson.

Janssen COVID-19 vaccine rollout in EU faces further delay

This development could further delay the rollout of the Janssen COVID-19 vaccine in the European Union. It was authorized in the EU on March 11 but the rollout of the shots has not started yet. The U.S. authorized the Janssen shot in late February and has administered nearly 5 million doses as of Thursday morning, April 8.

According to the EMA, it is still not clear yet whether there is a causal association between the vaccine and the blood clots. The EU’s top drug regulator will probe the cases and decide whether or not regulatory action is necessary.

Food and Drug Administration (FDA) documents detailing why it decided to authorize the Janssen shot include notes on a small number of patients developing blood clots after vaccination in a late-stage clinical trial.

The FDA said the causal relationship with the vaccine could not be determined because “the assessment of causality was confounded by the presence of underlying medical conditions that may have predisposed individuals to these events.”

Johnson & Johnson told the Epoch Times via email that it prioritizes the safety and well-being of people who use its products and that the company shares with health authorities all adverse event reports post-vaccination, along with its own assessment of each report.

“We are aware that thromboembolic events including those with thrombocytopenia have been reported with all COVID-19 vaccines. Our close tracking of side effects has revealed a small number of very rare events following vaccination. At present, no clear causal relationship has been established between these rare events and the Janssen COVID-19 vaccine,” Johnson & Johnson said.

The New Jersey-based pharmaceutical company added: “We continue to work closely with experts and regulators to assess the data and support the open communication of this information to healthcare professionals and the public to help ensure that, in the event of a very rare illness, appropriate steps can be taken for quick diagnosis and treatment.”

Johnson & Johnson said anyone who would experience symptoms such as swelling, shortness of breath and neurological difficulties after vaccination should immediately seek medical assistance.

views : 93 | images : 1 | Bookmark and Share


Enter your comment below



Leave a Reply

TORONTO BOOK PUBLISHING

Most Popular